ARTICLE | Clinical News
GT Biopharma leveraging NK cells to treat HIV
May 3, 2019 5:09 PM UTC
GT Biopharma is expanding its immuno-oncology platform into HIV thanks to work by its partner suggesting the company's TriKE modality could move the needle from life-long therapies to cures.
GT Biopharma Inc. (Pink:GTBP) said April 24 it will develop an HIV program using HIV-targeted Trispecific Killer Engagers (TriKEs) crafted by its long-time partners at the University of Minnesota...